Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

Jiawan Wang, Kai Pollard, Amy N. Allen, Tushar Tomar, Dirk Pijnenburg, Zhan Yao, Fausto J. Rodriguez, Christine A. Pratilas

Cancer Res (2020) 80 (23): 5367–5379.

https://doi.org/10.1158/0008-5472.CAN-20-1365

Published: 02 December 2020

View articletitled, Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

Includes: Supplementary data

Journal Articles

Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer

Cancer Res (2020) 80 (19): 4233–4243.

https://doi.org/10.1158/0008-5472.CAN-20-0865

Published: 02 October 2020

View articletitled, Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer

Includes: Supplementary data

Journal Articles

Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors

Xi Yuan, Xinwen Zhang, Rong Du, Shing-Hu Cheung, Min Wei, Changyou Zhou, Lai Wang, Todd Shearer, Badreddin Edris, Mary Smith, Zhan Yao, Claire N. Thant, Neal Rosen, Lusong Luo

Cancer Res (2020) 80 (16_Supplement): 6415.

https://doi.org/10.1158/1538-7445.AM2020-6415

Published: 15 August 2020

View articletitled, Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors

Journal Articles

Abstract LB-265: ARAF activates RAS by antagonizing its interaction with NF1

Wenjing Su, Rona Yaeger, Na Na, Jaclyn Hechtman, Viktoriya Paroder, Sandra Misale, Sae-Won Han, Omar I. Abdel-Wahab, Frank McCormick, Neal Rosen, Zhan Yao

Cancer Res (2019) 79 (13_Supplement): LB-265.

https://doi.org/10.1158/1538-7445.AM2019-LB-265

Published: 01 July 2019

View articletitled, Abstract LB-265: ARAF activates RAS by antagonizing its interaction with NF1

Journal Articles

Abstract 3184: A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor

Jiawan Wang, Zhan Yao, Philip Jonsson, Amy Allen, Alice Can Ran Qin, Sharmeen Uddin, Ira J. Dunkel, Mary Petriccione, Katia Manova, Sofia Haque, Marc Rosenblum, David J. Pisapia, Neal Rosen, Barry S. Taylor, Christine A. Pratilas

Cancer Res (2018) 78 (13_Supplement): 3184.

https://doi.org/10.1158/1538-7445.AM2018-3184

Published: 01 July 2018

View articletitled, Abstract 3184: A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor

Journal Articles

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Rona Yaeger, Zhan Yao, David M. Hyman, Jaclyn F. Hechtman, Efsevia Vakiani, HuiYong Zhao, Wenjing Su, Lu Wang, Andrew Joelson, Andrea Cercek, Jose Baselga, Elisa de Stanchina, Leonard Saltz, Michael F. Berger, David B. Solit, Neal Rosen

Cancer Res (2017) 77 (23): 6513–6523.

https://doi.org/10.1158/0008-5472.CAN-17-0768

Published: 30 November 2017

View articletitled, Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Includes: Supplementary data

Journal Articles

Abstract 395: Activation mechanisms of cancer associated MEK1 mutants

Yijun Gao, Matthew T. Chang, Daniel McKay, Rona D. Yaeger, Merna Torres, Keven Muniz, Drosten Matthias, Omar I. Abdel-Wahab, Mariano Barbacid, Giordano Caponigro, Darrin Stuart, David Solit, Barry S. Taylor, Zhan Yao, Neal Rosen

Cancer Res (2017) 77 (13_Supplement): 395.

https://doi.org/10.1158/1538-7445.AM2017-395

Published: 01 July 2017

View articletitled, Abstract 395: Activation mechanisms of cancer associated MEK1 mutants

Journal Articles

Abstract 4078: Tumors with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Zhan Yao, Rona Yaeger, Vanessa S. Rodrik-Outmezguine, Anthony Tao, Neilawattie M. Torres, Matthew T. Chang, Matthias Drosten, Huiyong Zhao, Fabiola Cecchi, Todd Hembrough, Judith Michels, Hervé Baumert, Linde Miles, Naomi M. Campbell, Elisa de Stanchina, David B. Solit, Mariano Barbacid, Barry S. Taylor, Neal Rosen

Cancer Res (2017) 77 (13_Supplement): 4078.

https://doi.org/10.1158/1538-7445.AM2017-4078

Published: 01 July 2017

View articletitled, Abstract 4078: Tumors with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Journal Articles

Abstract 2147: Overcoming mTOR resistance mutations with a new generation mTOR inhibitor

Vanessa S. Rodrik-Outmezguine, Masanori Okaniwa, Zhan Yao, Chris Novotny, Claire McWhirter, Arpitha Banaji, Helen Won, Wai Wong, Mike Berger, Elisa de Stanchina, Derek G. Barratt, Sabina Cosulich, Teresa Klinowska, Neal Rosen, Kevan M. Shokat

Cancer Res (2016) 76 (14_Supplement): 2147.

https://doi.org/10.1158/1538-7445.AM2016-2147

Published: 15 July 2016

View articletitled, Abstract 2147: Overcoming mTOR resistance mutations with a new generation mTOR inhibitor

Journal Articles

Abstract 3706: Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity

Zhan Yao, Merna Torres, Min Wei, Aphrothiti Hanrahan, Omar Abdel-Wahab, David Solit, Lusong Luo, Poulikos Poulikakos, Neal Rosen

Cancer Res (2014) 74 (19_Supplement): 3706.

https://doi.org/10.1158/1538-7445.AM2014-3706

Published: 01 October 2014

View articletitled, Abstract 3706: Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity

Journal Articles

Abstract 1726: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein

Vanessa S. Rodrik-Outmezguine, Zhan Yao, Radha Mukherjee, Liqun Cai, Derek Barratt, Richard Ward, Teresa Klinowska, Elisa D. Stanchina, Michael Berger, Jose Baselga, Neal Rosen

Cancer Res (2014) 74 (19_Supplement): 1726.

https://doi.org/10.1158/1538-7445.AM2014-1726

Published: 01 October 2014

View articletitled, Abstract 1726: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein

Journal Articles

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

Moriah H. Nissan, Christine A. Pratilas, Alexis M. Jones, Ricardo Ramirez, Helen Won, Cailian Liu, Shakuntala Tiwari, Li Kong, Aphrothiti J. Hanrahan, Zhan Yao, Taha Merghoub, Antoni Ribas, Paul B. Chapman, Rona Yaeger, Barry S. Taylor, Nikolaus Schultz, Michael F. Berger, Neal Rosen, David B. Solit

Cancer Res (2014) 74 (8): 2340–2350.

https://doi.org/10.1158/0008-5472.CAN-13-2625

Published: 15 April 2014

View articletitled, Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

Includes: Supplementary data

Journal Articles

Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling.

Marie Will, Weiyi Toy, Zhan Yao, Poulikos Poulikakos, Vanessa Rodrik-Outmezguine, Claudia Schneider, Juliane Paul, Jose Baselga, Ningshu Liu, Neal Rosen, Sarat Chandarlapaty

Cancer Res (2013) 73 (8_Supplement): 2321.

https://doi.org/10.1158/1538-7445.AM2013-2321

Published: 15 April 2013

View articletitled, Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors

Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer

Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors

Abstract LB-265: ARAF activates RAS by antagonizing its interaction with NF1

Abstract 3184: A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Abstract 395: Activation mechanisms of cancer associated MEK1 mutants

Abstract 4078: Tumors with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

Abstract 2147: Overcoming mTOR resistance mutations with a new generation mTOR inhibitor

Abstract 3706: Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity

Abstract 1726: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling.

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only